The effect of secukinumab treatment on inflammatory parameters in patients with psoriasis: A multicentre restrospective study
International Journal of Clinical Practice, cilt.75, sa.6, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 75 Sayı: 6
- Basım Tarihi: 2021
- Doi Numarası: 10.1111/ijcp.14114
- Dergi Adı: International Journal of Clinical Practice
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: Psoriasis is a common chronic inflammatory disease of the skin with remission and relapses. The aim of this study was to investigate the change in inflammatory parameters such as neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and mean platelet volume (MPV) in patients receiving secukinumab treatment for psoriasis vulgaris (PV). Materials and methods: In this retrospective study, we evaluated the laboratory results of 40 patients who were followed up with a diagnosis of PV and received secukinumab treatment in three different dermatology clinics between July 2018 and September 2019. Results: Neutrophil count and leukocyte count were significantly decreased after secukinumab treatment. (P <.001) There was no statistically significant difference between lymphocyte count, platelet count, MPV, NLR and PLR values before treatment and at the 4th month of treatment (P values.230,.065,.110,.915 and.365, respectively). Conclusion: In conclusion, it can be concluded that parameters such as NLR, PLR and MPV are not suitable parameters for monitoring the effects of secukinumab treatment on inflammation.